3 recruiting, 1 completed, 1 not yet recruiting. 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Metastatic Renal Cell Carcinoma ( mRCC): new trials by email Literature Review of Metastatic Renal Cell Carcinoma ( mRCC) trials Research Report on Metastatic Renal Cell Carcinoma ( mRCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) Fianlimab, Ipilimumab, Nivolumab - Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | Phase 2 | Recruiting | Brian Rini | 120 | 2026-04-29 | 2026-09-04 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC Ipilimumab plus Nivolumab, Cytoreductive Nephrectomy - Metastatic Renal Cell Carcinoma ( mRCC) | Not applicable | Not yet recruiting | Seoul National University Hospital | 172 | 2025-12-01 | 2025-12-03 |
| Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer IMSA101 - Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 15 | 2025-04-01 | 2025-11-12 |
| A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA) Sunitinib - Metastatic Renal Cell Carcinoma ( mRCC) | Completed | Pfizer | 57 | 2019-12-13 | 2022-05-10 |
Carcinoma, Renal Cell (5) · Neoplasm Metastasis (2) · Bites and Stings (1) · Carcinoma (1) · Clear-cell metastatic renal cell carcinoma (1) · Kidney Neoplasms (1) · Neoplasms (1)
Adenocarcinoma (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Carcinoma (4) · Kidney Neoplasms (4) · Neoplasms (4)
Ipilimumab (3) · Nivolumab (2) · Axitinib (1) · Sunitinib (1) · cemiplimab (1)
Pfizer (2) · Brian Rini (1) · Seoul National University Hospital (1) · University of Texas Southwestern Medical Center (1)
United States (3) · Argentina (1) · Australia (1) · Brazil (1) · China (1) · Colombia (1) · Ecuador (1) · Germany (1) · Japan (1) · Spain (1)
Brian Rini, MD (1) · Chang Wook Jeong, MD, PhD (1)
2025 (1)